Navitas Lifesciences proudly presents webinar on Risk Mitigation in Gene Therapy Clinical Trial Development. The webinar will include key challenges and issues related to

  • Optimum Patient Population: Stratification factors to be considered (clinical phenotypes supported by imaging/ biochemical/structural or morphological evidence)
  • Exclusion based on pre-existing neutralising antibodies
  • DSMB considerations in gene therapy clinical trials
  • Adverse Events of Special Interest: Immunogenicity, Insertional mutagenesis, off target effects
  • Patient centricity and retention in gene therapy trials

Speakers

Dr. Atul Gupta 
Associate Vice President,
Medical and Scientific Affairs
Navitas Life Sciences
Dr. Narendra Chirmule
CEO
SymphonyTech
Dr. Kirk Hammond
Professor of Medicine,
UC San Diego and Founder
Renova Therapeutics

Please complete the form to Register
First Name
Last Name
Business Email
Phone Number
Job Title
Company
Country
Live Webinar
Thursday 09, December 2021
Time: 10:00am – 11:00am EST

 

© 2021 Navitas Life Sciences | A TAKE Solutions Enterprise
Privacy Policy